GIBF

Silexion Therapeutics is a biotechnology company dedicated to developing innovative treatments for KRAS-driven cancers, particularly pancreatic cancer. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy delivered in an extended-release formulation, specifically designed for the treatment of locally advanced pancreatic cancer. Silexion is committed to advancing its clinical-stage oncology platform and is engaged in efforts to enhance the efficacy of its therapies, with plans for further clinical trials aimed at improving outcomes for patients with specific KRAS mutations.

BioVersys AG is a biopharmaceutical company based in Basel, specializing in the research and development of innovative therapies aimed at addressing multidrug-resistant bacterial infections. The company is dedicated to combating the growing global health challenge posed by bacterial drug resistance, which severely limits the effectiveness of current antibiotics. BioVersys employs its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to identify new treatments by targeting and inhibiting the mechanisms that confer resistance to bacterial pathogens. This approach not only enhances the efficacy of existing antibiotics but also provides healthcare professionals with new therapeutic options to treat life-threatening infections.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Kamari Pharma is a biopharmaceutical company focused on developing innovative treatments for unmet medical needs and rare diseases in dermatology. The company utilizes a proprietary platform to create small molecule inhibitors that address skin conditions lacking effective treatments. By targeting the underlying causes of serum calcium dysregulation, Kamari Pharma aims to provide solutions for various dermatological issues, thereby improving patient outcomes in a field where options are limited.

CoreBone develops a bioactive, 100% mineral bone graft material for dental, orthopedic, and spine procedures. The graft is created by embedding bioactive minerals into coral skeletons during their growth, producing a strong, porous material with predictable resorption not derived from human or animal bone. It is designed to accelerate healing and improve bone connectivity by offering a natural alternative to conventional grafts and reducing risks associated with human or animal bone. The company holds patents and know-how related to growing coral for medical applications.

Alpha Omega is a global medical technology company dedicated to enhancing patient care in neurology and neurosurgery. It specializes in developing advanced Microelectrode recording systems, which aid neurosurgeons in locating precise targets for deep brain stimulation electrode implantation, thereby improving surgical outcomes and facilitating neuroscience research. The company is renowned for its innovative products, consistent quality, and unwavering commitment to service excellence.